Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
D. Santagata, G. Cammà, M.P. Donadini, A. Squizzato & W. Ageno. (2022) Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients. Expert Opinion on Pharmacotherapy 23:14, pages 1651-1665.
Read now
Read now
Amal A. El-Masry, Abdallah M. Zeid, Dalia R. El-Wasseef, Manal Eid & Ihsan A. Shehata. (2020) A Validated Quantitative 1H Nuclear Magnetic Resonance (1H-qNMR) Method for Quantification of a Novel Anti-Coagulant Drug (Betrixaban Maleate) with Assessing Its Stability by Application to Degradation Study. Analytical Chemistry Letters 10:6, pages 768-783.
Read now
Read now
Daniele Scarpa, Gentian Denas, Luciano Babuin & Vittorio Pengo. (2019) The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients. Expert Opinion on Pharmacotherapy 20:3, pages 261-268.
Read now
Read now
Tarek Nafee, C. Michael Gibson, Megan K. Yee, Fahad Alkhalfan, Gerald Chi, Ryan Travis, Mahshid Mir, Arzu Kalayci, Mehrian Jafarizade, Aditya Ganti, Syed Hassan Kazmi, Eiman Ghaffarpasand, Anmol Pitliya, Sudarshana Datta, Sadaf Sharfaei, Mahda Alihashemi, Ahmed Elsaiey, Iqra Qamar, Mohamadmostafa Jahansouz, Usama Talib, Farima Kahe, Shaghayegh Habibi, Mohammed Abdelwahed, Feham Tariq, Manpreet Kaur, Ahmed Younes, Sargun S. Walia, Amandeep Singh, Syed Muhammad Dildar, M. Khurram Afzal & Mathieu Kerneis. (2018) Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. Expert Review of Cardiovascular Therapy 16:11, pages 845-855.
Read now
Read now
Jolanta Marszalek, Sara Mehrsefat & Gerald Chi. (2017) The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis. Expert Review of Hematology 10:8, pages 679-684.
Read now
Read now
Tiffany Y Hu, Vaibhav R Vaidya & Samuel J Asirvatham. (2016) Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vascular Health and Risk Management 12, pages 35-44.
Read now
Read now
Martin Thoenes, Joan Minguet, Karin Bramlage, Peter Bramlage & Carmen Ferrero. (2016) Betrixaban – the next direct factor Xa inhibitor?. Expert Review of Hematology 9:12, pages 1111-1117.
Read now
Read now
Benilde Cosmi. (2016) An update on the pharmaceutical management of thrombosis. Expert Opinion on Pharmacotherapy 17:16, pages 2149-2164.
Read now
Read now
Andrew Blann. (2015) Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in. Vascular Health and Risk Management 11, pages 489-492.
Read now
Read now
Articles from other publishers (9)
Nikunj PatadiyaVipul Vaghela. (2022) Design, in-silico ADME Study and molecular docking study of novel quinoline-4-on derivatives as Factor Xa Inhibitor as Potential anti-coagulating agents. Asian Journal of Pharmaceutical Research, pages 207-211.
Crossref
Crossref
Grzegorz Grześk, Daniel Rogowicz, Łukasz Wołowiec, Agnieszka Ratajczak, Wojciech Gilewski, Małgorzata Chudzińska, Anna Sinkiewicz & Joanna Banach. (2021) The Clinical Significance of Drug–Food Interactions of Direct Oral Anticoagulants. International Journal of Molecular Sciences 22:16, pages 8531.
Crossref
Crossref
Donald J. AbrahamMimi L. Quan, Peter W. Glunz & Joseph M. Luettgen. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
45
.
Claire Dunois. (2021) Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). Biomedicines 9:5, pages 445.
Crossref
Crossref
Kathrin I. Foerster, Simon Hermann, Gerd Mikus & Walter E. Haefeli. (2020) Drug–Drug Interactions with Direct Oral Anticoagulants. Clinical Pharmacokinetics 59:8, pages 967-980.
Crossref
Crossref
Kaisheng Deng, Jinqun Cheng, Shufang Rao, Huafu Xu, Lixia Li & Yanhui Gao. (2020) Efficacy and Safety of Direct Oral Anticoagulants in Elderly Patients With Atrial Fibrillation: A Network Meta-Analysis. Frontiers in Medicine 7.
Crossref
Crossref
Tara L. Knotts & Shaker A. Mousa. (2019) Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs. American Journal of Cardiovascular Drugs 19:4, pages 365-376.
Crossref
Crossref
Michael Bowie, Violet Valencia, Ingrid Perez-Alvarez & Minh-Ha Tran. (2018) Safety analysis of apixaban versus warfarin in patients with advanced kidney disease. Journal of Thrombosis and Thrombolysis 46:2, pages 246-252.
Crossref
Crossref
Scott G. Garland, Christina E. DeRemer, Steven M. Smith & John G. Gums. (2018) Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients. Annals of Pharmacotherapy 52:6, pages 554-561.
Crossref
Crossref